Not for human or veterinary administration. Listed strength is a supplied specification; see the matching batch report for measured results.
Batch documentation
1 report is available for this strength. Match the reported sample and available batch identifiers; contact support if the link to your vial is unclear.
Retatrutide is a peptide that activates three hormone receptors: GLP-1, GIP and glucagon. These pathways influence appetite, blood-glucose regulation and energy metabolism. Researchers have investigated it in controlled clinical trials for obesity and related metabolic questions.
What is it studied for?
Weight and appetite regulation
GLP-1, GIP and glucagon receptor activity
Metabolic responses to combined hormone signalling
EXPLORE THE EVIDENCE
Studies & research references
Each source identifies what was studied and the limits of its findings. Published research is separate from this product’s batch COA.
A controlled obesity trial investigated weight change and adverse events with an investigational retatrutide formulation. The study did not assess the identity or effectiveness of this catalogue vial.
A randomised trial compared an investigational formulation with placebo and dulaglutide in adults with type 2 diabetes. It examined HbA1c, body weight and adverse events; it did not test this catalogue product.
RETATRUTIDE is currently listed in 10 mg, 20 mg, 30 mg. Select a strength above to see its price, product image and current stock. Listed quantities are supplied specifications, not measured batch results.
Is a COA available for RETATRUTIDE?
5 laboratory reports are published for this compound. Match the selected strength and available batch identifiers, and open the original document to check the actual test scope.
The references discuss the material and experimental conditions in those studies. They do not verify the identity, purity, quantity or suitability of this catalogue vial. Review the study limitations and the available batch documentation separately.